US5639724A
(en)
|
1984-07-24 |
1997-06-17 |
Sandoz Ltd. |
Cyclosporin galenic forms
|
GB8904182D0
(en)
*
|
1989-02-23 |
1989-04-05 |
Glaxo Canada |
Pharmaceutical compositions
|
HU208491B
(en)
*
|
1990-11-27 |
1993-11-29 |
Gyogyszerkutato Intezet |
Process for producing oral pharmaceutical composition containing cyclosporin
|
IL102236A0
(en)
*
|
1991-06-27 |
1993-01-14 |
Ltt Inst Co Ltd |
Topical preparations containing cyclosporin
|
GB9113872D0
(en)
*
|
1991-06-27 |
1991-08-14 |
Sandoz Ag |
Improvements in or relating to organic compounds
|
AU688920B2
(en)
*
|
1991-06-27 |
1998-03-19 |
Novartis Ag |
Transesterified corn oil products
|
US6262022B1
(en)
|
1992-06-25 |
2001-07-17 |
Novartis Ag |
Pharmaceutical compositions containing cyclosporin as the active agent
|
DK0642332T3
(en)
|
1992-05-13 |
1997-06-16 |
Sandoz Ltd |
Ophthalmic preparations containing cyclosporin
|
US5759566A
(en)
*
|
1992-07-28 |
1998-06-02 |
Poli Industria Chimica Spa |
Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
|
PT589843E
(en)
|
1992-09-25 |
2002-04-29 |
Novartis Ag |
PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORTS
|
CZ291237B6
(en)
†
|
1993-04-20 |
2003-01-15 |
Novartis Ag |
Pharmaceutical preparation for oral administration and containing cyclosporin A
|
DE4412201A1
(en)
*
|
1993-04-20 |
1994-11-10 |
Rentschler Arzneimittel |
New pharmaceutical preparations for oral administration containing cyclosporin
|
NZ247516A
(en)
*
|
1993-04-28 |
1995-02-24 |
Bernard Charles Sherman |
Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
|
DE4322826A1
(en)
*
|
1993-07-08 |
1995-01-12 |
Galenik Labor Freiburg Gmbh |
Pharmaceutical preparation
|
DE4340781C3
(en)
*
|
1993-11-30 |
2000-01-27 |
Novartis Ag |
Liquid preparations containing cyclosporin and process for their preparation
|
WO1995022343A1
(en)
*
|
1994-02-17 |
1995-08-24 |
Shiseido Company, Ltd. |
Cyclosporin-containing emulsion composition
|
US5891846A
(en)
*
|
1994-02-17 |
1999-04-06 |
Shiseido Company, Ltd. |
Cyclosporin-containing emulsion composition
|
GB9405304D0
(en)
*
|
1994-03-16 |
1994-04-27 |
Scherer Ltd R P |
Delivery systems for hydrophobic drugs
|
US5474979A
(en)
*
|
1994-05-17 |
1995-12-12 |
Allergan, Inc. |
Nonirritating emulsions for sensitive tissue
|
RU2158601C2
(en)
|
1994-11-03 |
2000-11-10 |
Новартис Аг |
Novel medicinal forms of cyclosporine for oral administration having simple formulation and bioavailability, and method of preparation thereof
|
US5603951A
(en)
*
|
1994-11-09 |
1997-02-18 |
Hanmi Pharm. Ind. Co., Ltd. |
Cyclosporin-containing soft capsule compositions
|
KR0167613B1
(en)
*
|
1994-12-28 |
1999-01-15 |
한스 루돌프 하우스, 니콜 케르커 |
Cyclosporin-containing soft capsule compositions
|
US5834017A
(en)
*
|
1995-08-25 |
1998-11-10 |
Sangstat Medical Corporation |
Oral cyclopsporin formulations
|
US5962019A
(en)
*
|
1995-08-25 |
1999-10-05 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US5766629A
(en)
*
|
1995-08-25 |
1998-06-16 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US5827822A
(en)
*
|
1996-03-25 |
1998-10-27 |
Sangstat Medical Corporation |
Cyclosporin a formulations as nanoparticles
|
DE19544507B4
(en)
|
1995-11-29 |
2007-11-15 |
Novartis Ag |
Cyclosporin containing preparations
|
CZ288631B6
(en)
*
|
1996-01-18 |
2001-08-15 |
Galena, A. S. |
Therapeutic preparations containing cyclosporin
|
US5858401A
(en)
|
1996-01-22 |
1999-01-12 |
Sidmak Laboratories, Inc. |
Pharmaceutical composition for cyclosporines
|
CA2278675A1
(en)
|
1997-01-30 |
1998-08-06 |
Novartis Ag |
Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil
|
JP4718653B2
(en)
*
|
1997-03-12 |
2011-07-06 |
アボツト・ラボラトリーズ |
Hydrophilic two-component system for administration of cyclosporine
|
JP2001515491A
(en)
*
|
1997-03-12 |
2001-09-18 |
アボツト・ラボラトリーズ |
Lipophilic binary system for administration of lipophilic compounds
|
DK0989851T3
(en)
*
|
1997-07-29 |
2003-01-27 |
Upjohn Co |
Self-emulsifying formulation containing acidic lipophilic compounds
|
WO1999006043A1
(en)
|
1997-07-29 |
1999-02-11 |
Pharmacia & Upjohn Company |
Self-emulsifying formulation for lipophilic compounds
|
US6346511B1
(en)
|
1997-09-08 |
2002-02-12 |
Panacea Biotec Limited |
Pharmaceutical composition comprising cyclosporin
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
US6008191A
(en)
*
|
1997-09-08 |
1999-12-28 |
Panacea Biotec Limited |
Pharmaceutical compositions containing cyclosporin
|
US5981607A
(en)
*
|
1998-01-20 |
1999-11-09 |
Allergan |
Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
|
ID25908A
(en)
*
|
1998-03-06 |
2000-11-09 |
Novartis Ag |
EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
|
DE19859910C2
(en)
*
|
1998-12-23 |
2001-03-22 |
Ratiopharm Gmbh |
Oral medicine
|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
GB9912476D0
(en)
|
1999-05-28 |
1999-07-28 |
Novartis Ag |
Organic compounds
|
AU2127400A
(en)
*
|
1999-11-02 |
2001-05-14 |
Cipla Limited |
A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and process for preparation thereof
|
GB2362573A
(en)
*
|
2000-05-25 |
2001-11-28 |
Cipla Ltd |
Cyclosporin formulation
|
PT1151755E
(en)
*
|
2000-05-04 |
2005-05-31 |
Panacea Biotec Ltd |
PHARMACEUTICAL COMPOSITIONS UNDERSTANDING CYCLOSPORIN AS AN ACTIVE SUBSTANCE
|
DE10030378A1
(en)
*
|
2000-06-21 |
2002-03-14 |
Audit Inst For Medical Service |
New pharmaceutical composition for topical application of water-insoluble and / or poorly water-soluble active ingredients
|
US6979672B2
(en)
|
2002-12-20 |
2005-12-27 |
Polichem, S.A. |
Cyclosporin-based pharmaceutical compositions
|
JP4381037B2
(en)
|
2003-06-04 |
2009-12-09 |
花王株式会社 |
Oil composition
|
US8673351B2
(en)
|
2005-03-21 |
2014-03-18 |
Ivax Pharmaceuticals S.R.O. |
Crystallization inhibitor and its use in gelatin capsules
|
US8492369B2
(en)
|
2010-04-12 |
2013-07-23 |
Clarus Therapeutics Inc |
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
|
EP2985026B1
(en)
|
2005-04-15 |
2022-08-03 |
Clarus Therapeutics, Inc. |
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
|
FR2914188B1
(en)
*
|
2007-03-28 |
2012-06-22 |
Trophos |
NEW CHOLEST-4-EN-3-ONE OXIME COMPOSITION
|
GB2451811A
(en)
|
2007-08-09 |
2009-02-18 |
Ems Sa |
Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
CA2690490C
(en)
*
|
2010-01-19 |
2012-06-26 |
Accucaps Industries Limited |
Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
ES2944263T3
(en)
*
|
2014-01-16 |
2023-06-20 |
Maruho Kk |
Topical agent for transdermal administration
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
CA3078723A1
(en)
|
2016-11-28 |
2018-05-31 |
Nachiappan Chidambaram |
Oral testosterone undecanoate therapy
|
EA202192793A1
(en)
|
2019-04-11 |
2022-01-12 |
Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи |
COMPOSITION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH WEAK PERMEABILITY
|